Agile Therapeutics’ Twirla could carve out meaningful share in US contraceptive market

Agile Therapeutics’ Twirla (ethinyl estradiol + levonorgestrel) could have an edge over competitors based on milder side-effects and a potentially safer profile, says GlobalData, a leading data and analytics company.

As the largest contraceptives market, the US will experience moderate growth at a compound annual growth rate (CAGR) of 4.8%, reaching $5.2bn total sales by 2027. This market offers several options, including both on-demand and longer-acting approaches, and has been dominated by intrauterine devices and oral contraceptives during the past decade.

Despite Twirla’s rocky regulatory history, it will become the only low-dose combination hormonal contraceptive patch, once it hits the market. Moreover, as Twirla delivers a much lower dose of ethinyl estradiol per day compared to the only similar approved option, namely the high-dose Xulane patch, it could have an edge over Xulane.

Kelly Lambrinos, Senior Pharma Analyst at GlobalData, comments: “Compliance difficulties are more common among oral contraceptive users, while other long-lasting forms, such as hormonal intrauterine devices, tend to cause various unwanted side effects. As there is a need in the female contraception space for a method that is not an inserted device or an ingested pill, the demand for a novel weekly transdermal option will be evident and there is space for Twirla’s addition to the current US market.

“However, there still remains a need for more alternatives, and particularly, non-hormonal options. Key opinion leaders (KOLs) interviewed by GlobalData have expressed that there are some women who remain hesitant in taking hormonal contraceptives because of the associated side effects.”

More Media